Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-PRPH2-001 in PRPH2-associated Retinal Dystrophy
NCT07177196Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of nL-PRPH2-001 in retinal dystrophy, sponsored by n-Lorem Foundation. Started Aug 2025; status: active, not recruiting.
02
Drugs
nL-PRPH2-001
03
Conditions
retinal dystrophy
Beyond the preview
Go deeper on NCT07177196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177196.